Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oteseconazole - Mycovia Pharmaceuticals

Next Previous
Drug Profile

Oteseconazole - Mycovia Pharmaceuticals

Alternative Names: SHR-8008; VIVJOA; VT-1161

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Viamet Pharmaceuticals
  • Developer Jiangsu Hengrui Medicine Co.; Mycovia Pharmaceuticals; Viamet Pharmaceuticals
  • Class Antifungals; Fluorinated hydrocarbons; Fluorobenzenes; Foot disorder therapies; Phenyl ethers; Propanols; Pyridines; Small molecules; Tetrazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Vulvovaginal candidiasis
  • Phase II Onychomycosis
  • Phase I Coccidioidomycosis; Cryptococcosis; Immunocompromised infections; Invasive candidiasis
  • Discontinued Tinea pedis

Most Recent Events

  • 02 Apr 2025 VIVJOA is included in the National Reimbursement Drug List for treating severe vulvovaginal candidiasis in China
  • 29 Feb 2024 Phase-I clinical trials in Coccidioidomycosis (unspecified route) Prior to February 2024 (Mycovia Pipeline, February 2024)
  • 29 Feb 2024 Phase-I clinical trials in Cryptococcosis (unspecified route) Prior to February 2024 (Mycovia Pipeline, February 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top